Frontiers
Browse
DataSheet1_Epigenetic Regulation of miR-92a and TET2 and Their Association in Non-Hodgkin Lymphoma.docx (802.79 kB)

DataSheet1_Epigenetic Regulation of miR-92a and TET2 and Their Association in Non-Hodgkin Lymphoma.docx

Download (802.79 kB)
dataset
posted on 2021-11-26, 05:06 authored by Esther K. Elliott, Lloyd N. Hopkins, Robert Hensen, Heidi G. Sutherland, Larisa M. Haupt, Lyn R. Griffiths

MicroRNAs (miRNAs) are well known for their ability to regulate the expression of specific target genes through degradation or inhibition of translation of the target mRNA. In various cancers, miRNAs regulate gene expression by altering the epigenetic status of candidate genes that are implicated in various difficult to treat haematological malignancies such as non-Hodgkin lymphoma by acting as either oncogenes or tumour suppressor genes. Cellular and circulating miRNA biomarkers could also be directly utilised as disease markers for diagnosis and monitoring of non-Hodgkin lymphoma (NHL); however, the role of DNA methylation in miRNA expression regulation in NHL requires further scientific inquiry. In this study, we investigated the methylation levels of CpGs in CpG islands spanning the promoter regions of the miR-17–92 cluster host gene and the TET2 gene and correlated them with the expression levels of TET2 mRNA and miR-92a-3p and miR-92a-5p mature miRNAs in NHL cell lines, tumour samples, and the whole blood gDNA of an NHL case control cohort. Increased expression of both miR-92a-3p and miR-92a-5p and aberrant expression of TET2 was observed in NHL cell lines and tumour tissues, as well as disparate levels of dysfunctional promoter CGI methylation. Both miR-92a and TET2 may play a concerted role in NHL malignancy and disease pathogenesis.

History